diabetic kidney disease

Advertisement
Charlotte RobinsonDiabetes and Hypertension | February 28, 2025
SC0062 met the 12-week primary end point of a reduction in proteinuria in a study cohort with diabetic kidney disease (DKD).
Read More
Charlotte RobinsonChronic Kidney Disease | February 10, 2025
Using NURTuRE-CKD data, researchers studied kidney outcomes and heterogeneity of risk by primary renal diagnosis.
Charlotte RobinsonChronic Kidney Disease | February 7, 2025
Monlunabant failed in a study of its use in DKD, but Novo Nordisk had positive news about other kidney treatments in 2024.
Charlotte RobinsonASN Kidney Week 2024 | December 5, 2024
A study examined the efficacy of adding SZC to allow patients with stage 3-4 DKD to maintain treatment with RAASi.
Charlotte RobinsonDiabetes and Hypertension | August 23, 2024
Researchers tried to determine whether eGFR slope is a predictor of type 2 diabetes complications.
Charlotte RobinsonDiabetes and Hypertension | September 18, 2024
A study examined the association of HbA1c with mortality in patients with chronic kidney disease and type 2 diabetes.
Charlotte RobinsonHyperkalemia | September 3, 2024
Researchers assessed the landscape of QSP modeling and developed a use case for QSP to determine hyperkalemia risk.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | August 23, 2024
The four-pillar approach to treating diabetic kidney disease (DKD) has been endorsed by high-quality trials, such as FLOW. 
Ajay K. Singh, MBBS, FRCP, MBANKF Spring Clinical Meetings 2024 | May 29, 2024
Ajay K. Singh discussed his findings on daprodustat dosing and utilization of finerenone.
Victoria SochaDiabetes and Hypertension | May 14, 2024
Could urinary podocyte stress biomarker be a surrogate marker of podocyte injury in diabetic kidney disease (DKD)?
Charlotte RobinsonDiabetes and Hypertension | March 29, 2024
Medicare Part D spending on GLP-1 drugs has soared to $5.7 billion, straining Medicare spending.
Charlotte RobinsonDiabetes and Hypertension | March 29, 2024
Current practice guidelines do not address dietary management specific to diabetic kidney disease (DKD).
Victoria SochaKidney Transplantation | February 5, 2024
The most common primary renal disease in patients initiating renal replacement therapy is diabetes.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Several classes of glucose-lowering drugs have been shown to have kidney benefits in patients with type 2 diabetes.
Victoria SochaDiabetes and Hypertension | February 5, 2024
The most common concomitant medication classes were antihypertensives (95%), antihyperglycemic (81%), and statins (79%).
Victoria SochaDiabetes and Hypertension | February 5, 2024
Preliminary evidence has demonstrated preservation of kidney function as measured by eGFR compared with baseline.
Victoria SochaHyperkalemia | February 5, 2024
There was a five-fold higher risk of hyperkalemia with use of a steroidal MRA plus an ACEi or ARB.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Assessing the early impact of risk categorization on management of patients with DKD.
Victoria SochaDiabetes and Hypertension | February 5, 2024
Gaps in care in treating proteinuria in patients with DKD.
Victoria SochaNephrology Times | February 5, 2024
In the population of patients with chronic kidney disease (CKD), particularly those with diabetes as the underlying ...
Advertisement
Advertisement
Advertisement
Latest News

March 18, 2025